Pluronic Polymer-Based Ormeloxifene Nanoformulations Induce Superior Anticancer Effects in Pancreatic Cancer Cells.
Journal
ACS omega
ISSN: 2470-1343
Titre abrégé: ACS Omega
Pays: United States
ID NLM: 101691658
Informations de publication
Date de publication:
21 Jan 2020
21 Jan 2020
Historique:
received:
11
10
2019
accepted:
16
12
2019
entrez:
28
1
2020
pubmed:
28
1
2020
medline:
28
1
2020
Statut:
epublish
Résumé
Utilization of safe cytotoxic agents with precise anticancer activity is considered as the prime focus of cancer therapeutics research. A greater incentive for such agents arises from the molecules/drugs that are already being used for other indications. Ormeloxifene (ORM) is a nonsteroidal, nonhormonal selective estrogen receptor modulator (SERM), which has been in human use for contraception purposes. Although in the recent past, many reports have suggested its emerging role as an anticancer agent, no significant attention was paid toward generating simple and safe nanoformulation(s) for improved therapeutic activity and tumor cell-specific delivery. Our aim is to develop nanoformulation(s) of ormeloxifene to improve its targeted delivery in tumor cells. We developed ormeloxifene nanoformulation(s) by utilizing various biocompatible polymers. The optimized formulations with pluronic polymers F127 and F68 show improved nanoparticle characteristics. These formulations show enhanced cellular uptake that allows ormeloxifene's intracellular availability. We further evaluated its improved anticancer activity by performing cell proliferation, flow cytometry, and immunoblotting assays. Overall, this study confirms possible novel nanoformulation(s) of ormeloxifene to be evolved as a new therapeutic modality for cancer treatment.
Identifiants
pubmed: 31984272
doi: 10.1021/acsomega.9b03382
pmc: PMC6977081
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1147-1156Subventions
Organisme : NCI NIH HHS
ID : R01 CA204552
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA206069
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA210192
Pays : United States
Informations de copyright
Copyright © 2020 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Curr Pharm Des. 2006;12(36):4669-84
pubmed: 17168771
Nat Nanotechnol. 2007 Dec;2(12):751-60
pubmed: 18654426
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Adv Drug Deliv Rev. 2004 Sep 22;56(11):1649-59
pubmed: 15350294
Invest New Drugs. 2011 Oct;29(5):1029-37
pubmed: 20179989
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Cold Spring Harb Protoc. 2016 Aug 01;2016(8):
pubmed: 27480718
Proteomics. 2011 Apr;11(8):1517-29
pubmed: 21360677
Expert Opin Ther Targets. 2011 Jul;15(7):817-28
pubmed: 21391891
Am J Transplant. 2017 Aug;17(8):1974-1991
pubmed: 28394486
Curr Drug Targets. 2011 Jul 1;12(8):1112-30
pubmed: 21443477
Eur J Pharm Biopharm. 1999 Sep;48(2):101-11
pubmed: 10469928
Apoptosis. 2002 Aug;7(4):321-8
pubmed: 12101391
Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6939-42
pubmed: 9192670
Mol Cancer Ther. 2017 Oct;16(10):2267-2280
pubmed: 28615299
World J Gastroenterol. 2004 Jun 1;10(11):1551-4
pubmed: 15162523
Angew Chem Int Ed Engl. 2014 Nov 10;53(46):12320-64
pubmed: 25294565
World J Gastroenterol. 2014 Jul 28;20(28):9354-60
pubmed: 25071330
Med Res Rev. 2001 Jul;21(4):302-47
pubmed: 11410933
Apoptosis. 2003 Mar;8(2):115-28
pubmed: 12766472
Carbohydr Res. 2006 May 1;341(6):744-56
pubmed: 16499893
Drug Discov Today. 2010 Oct;15(19-20):842-50
pubmed: 20727417
Int J Nanomedicine. 2012;7:591-605
pubmed: 22346353
Toxicol Pathol. 2007 Jun;35(4):495-516
pubmed: 17562483
Cell Biol Int. 2015 Aug;39(8):881-90
pubmed: 25790433
Biomaterials. 2015;53:731-43
pubmed: 25890768
Sci Rep. 2019 Jul 29;9(1):10917
pubmed: 31358785
J Control Release. 2015 Feb 28;200:138-57
pubmed: 25545217
Nano Lett. 2006 Nov;6(11):2427-30
pubmed: 17090068
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cancer Lett. 2015 Jan 28;356(2 Pt B):606-12
pubmed: 25306892
Eur J Pharm Biopharm. 2015 Jun;93:52-79
pubmed: 25813885
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
Mutagenesis. 1999 Nov;14(6):613-20
pubmed: 10567037
Am Fam Physician. 2014 Apr 15;89(8):626-32
pubmed: 24784121
Biomaterials. 2011 Mar;32(7):1890-905
pubmed: 21167595
Int J Cancer. 1989 May 15;43(5):781-3
pubmed: 2714882
Curr Drug Metab. 2012 Jan;13(1):120-8
pubmed: 21892919
J Colloid Interface Sci. 2010 Nov 1;351(1):19-29
pubmed: 20627257
J Control Release. 2005 Dec 5;109(1-3):169-88
pubmed: 16289422
Nanomedicine. 2010 Dec;6(6):714-29
pubmed: 20542144
J Clin Oncol. 2009 Nov 20;27(33):5513-8
pubmed: 19858379
Eur J Cancer. 2011 Jul;47(11):1676-81
pubmed: 21565490
Nature. 2001 May 17;411(6835):342-8
pubmed: 11357141
Int J Biol Macromol. 2006 May 30;38(3-5):272-83
pubmed: 16620951
Int J Nanomedicine. 2019 Sep 03;14:7107-7121
pubmed: 31564868
Indian J Exp Biol. 1977 Dec;15(12):1144-50
pubmed: 96021
JAMA. 2008 Mar 5;299(9):1019-26
pubmed: 18319412
Biochem Biophys Res Commun. 2011 Jan 7;404(1):40-5
pubmed: 21094138
Clin Cancer Res. 2008 Mar 1;14(5):1310-6
pubmed: 18316549
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Jan;9(1):
pubmed: 27312983
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Cancer Res. 2015 Jun 1;75(11):2292-304
pubmed: 25840985
Contraception. 1998 Jul;58(1):61-8
pubmed: 9743898
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Adv Drug Deliv Rev. 2014 Feb;66:2-25
pubmed: 24270007
AAPS J. 2016 Nov;18(6):1351-1353
pubmed: 27520380
Colloids Surf B Biointerfaces. 2010 Aug 1;79(1):113-25
pubmed: 20456930